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CASE REPORT

DRESS induced by amoxicillin‑clavulanate
in two pediatric patients confirmed
by lymphocyte toxicity assay
Arun Dhir1* , Hasandeep Kular2, Abdelbaset A. Elzagallaai3,4,5, Bruce Carleton6,7,8, Michael J. Rieder3,4,9,
Raymond Mak2 and Tiffany Wong10

Abstract
Background: Drug reaction with eosinophilia and systemic symptoms (DRESS) is a rare but serious delayed
hypersensitivity reaction that can be caused by antibiotic exposure. The reaction typically develops in 2 to 6 weeks.
The pathophysiology is thought to involve toxic drug metabolites acting as a hapten, triggering a systemic response.
The diagnosis is made clinically but can be confirmed using assays such as the lymphocyte toxicity assay (LTA), which
correlates cell death upon exposure to drug metabolites with susceptibility to hypersensitivity reactions.
Case presentations: Case 1 involves a previously healthy 11-month-old male with first exposure to amoxicillinclavulanate, prescribed for seven days to treat a respiratory infection. The patient developed DRESS fourteen days after
starting the drug and was successfully treated with corticosteroids. LTA testing confirmed patient susceptibility to
hypersensitivity reactions with amoxicillin-clavulanate. Parental samples were also tested, showing both maternal and
paternal susceptibility. Neither parent reported prior hypersensitivity reactions. Lifelong penicillin avoidance for the
patient was advised along with the notation in medical records of penicillin allergy. The parents were advised to avoid
penicillin class antibiotics and be monitored closely for DRESS if they are exposed.
Case 2 involves an 11-year-old female with atopic dermatitis with first exposure to amoxicillin-clavulanate, prescribed
for ten days to treat a secondary bacterial skin infection. She developed DRESS eleven days after starting antibiotics
and was successfully treated with corticosteroids. LTA testing confirmed patient susceptibility to hypersensitivity
reactions with amoxicillin-clavulanate. Maternal samples were also tested and showed sensitivity. The mother
reported no prior hypersensitivity reactions. Lifelong penicillin avoidance for the patient was advised along with the
notation in medical records of penicillin allergy.
Conclusions: Amoxicillin-clavulanate is a commonly used antibiotic and the cases we have described suggest that
it should be recognized as a potential cause of DRESS in pediatric patients. Furthermore, these cases contribute to
current literature supporting that there may be a shorter latent period in DRESS induced by antibiotics. We have also
shown that the LTA can be a helpful tool to confirm DRESS reactions, and that testing may have potential implications
for family members.
Keywords: “Drug reaction with eosinophilia and systemic symptoms”, DRESS, Lymphocyte Toxicity Assay, Antibiotics,
Amoxicillin-clavulanate
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Background
Drug reaction with eosinophilia and systemic symptoms
(DRESS) is a rare but potentially fatal delayed
hypersensitivity reaction. It is hypothesized that the
reaction involves a combination of the activation of
drug-specific T-lymphocytes, latent viral reactivation,
accumulation of reactive drug metabolites, as well as
genetic predisposition [1]. The toxic metabolite acts
as a hapten, initiating an immune response. DRESS is
classically associated with anticonvulsant agents, but
15–37% of DRESS cases may be due to antibiotics,
[2] with one with study reporting up to 74% (39% to
vancomycin, 23% to beta-lactams) [3]. The reaction
typically has a latency period of 2 to 6 weeks [2, 4].
Symptoms include fever, diffuse rash, lymphadenopathy,
hematologic abnormalities (eosinophilia, atypical
lymphocytosis), and ultimately internal organ
involvement [2]. This diagnosis is made clinically,
often supported by tools such as the European Registry
of Severe Cutaneous Adverse Reaction (RegiSCAR)
validation scoring criteria [5].
Additional tools that may be used to confirm a
diagnosis of DRESS include patch testing and in-vitro
assays. The lymphocyte toxicity assay (LTA) is one such
assay based upon based upon the premise that DRESS
may be triggered by accumulation of toxic metabolites
[6]. The patient’s lymphocytes, isolated from peripheral
blood samples and acting as a surrogate for target tissue

cells, are incubated with the suspected drug in presence of
phenobarbital-induced mammalian hepatic microsomes
as a source of cytochrome P450 monooxygenase
activity. The degrees of cell death in samples isolated
from patients and from healthy volunteers are then
quantified and compared. Enhancement of cell death is
hypothesized to correlate with the patient’s susceptibility
to developing hypersensitivity reactions to the agent
being tested.
Here, we present two cases of pediatric patients with
DRESS induced by amoxicillin-clavulanate and the
results of their LTA testing.

Case presentations
Case 1 involves a previously healthy 11-month-old male
with first exposure to amoxicillin-clavulanate, prescribed
for seven days to treat a respiratory infection. Fourteen
days after starting antibiotics, he presented with fevers,
lethargy, and a widespread generalized erythematous
maculopapular rash. Laboratory investigations showed
reactive lymphocytes, peripheral eosinophilia, and
hepatitis. Testing for ANA, hepatitis A and B, EBV,
CMV, HHV6, mycoplasma, chlamydia, and blood
cultures were negative. A RegiSCAR Diagnosis Score
of 6 confirmed definite DRESS (Table 1). The patient
received systemic steroids, resulting in normalization
of lab work and improvement of symptoms. LTA testing
showed a concentration-dependent decline in viability in

Table 1 RegiSCAR Scoring System for Classifying DRESS Cases, adapted from Cho et al. [5] applied to patients described in Case 1 and
Case 2
Items

Score
−1

Fever ≧ 38.5 °C

N/U

0

Comments

Case 1 score

Case 2 score

1
0

0

Enlarged lymph nodes

N/U

Y

> 1 cm and ≧ 2 different areas

0

0

Eosinophilia ≧ 0.7 × 109/L or ≧
10% if WBC < 4.0 × 109/L

N/U

Y

Score 2, when ≧ 1.5 × 109/L or ≧ 20% if WBC < 4.0 × 109/L

1

1

N/U

Y

1

0

Atypical lymphocytosis

Y

Skin rash
Extent > 50% of BSA
Rash suggesting DRESS

N

Skin biopsy suggesting DRESS

N

Organ involvement
Rash resolution ≧ 15 days
Excluding other causes

Total score

N/U

Y

U

Y

Y/U
N

N/U

Rash suggesting DRESS: ≧ 2 symptoms: purpuric lesions
(other than legs), infiltration, facial edema, psoriasiform
desquamation

1
1

0

0

Y

Score 1 for each organ involvement, maximal score: 2

1

1

0

0

Y

Score 1 if 3 tests of the following tests were performed
and all were negative: HAV, HBV, HCV, Mycoplasma,
Chlamydia, ANA, blood culture

1

1

6

5

Y
N/U

1
1

The diagnosis of DRESS syndrome is then made based on the total score: < 2 points: no case; 2–3 points: possible case; 4–5 points: probable case; > 5 points: definite
case
ANA: anti-nuclear antibody; BSA: body surface area; HAV: hepatitis A virus; HBV: hepatitis B virus; HCV: hepatitis C virus; N: no; U: unknown; WBC: white blood cell; Y:
yes

Dhir et al. Allergy Asthma Clin Immunol

(2021) 17:37

the patient’s white blood cells compared to controls after
incubation with penicillin and its metabolites (Fig. 1).
Lifelong penicillin avoidance was advised along with the
notation in medical records of penicillin allergy. Parental
samples were tested, showing a concentration-dependent
decline in cell viability when exposed to penicillin and
its metabolites. Neither parent reported prior adverse
reactions to antibiotics. They were counselled that the
implications of a positive LTA without a prior reaction
are unknown. They were also advised that alternatives
to penicillin class antibiotics should be used to treat
infections, and that if exposed to such antibiotics, they
should be monitored closely for symptoms of DRESS.
Case 2 involves an 11-year-old female with atopic
dermatitis with a first exposure to amoxicillinclavulanate, prescribed for ten days to treat a secondary
bacterial skin infection. She developed fevers and
decreased appetite eleven days after starting antibiotics.
This progressed to diffuse erythrodermic, maculopapular
eruption, superficial desquamation, facial angioedema,
peripheral eosinophilia, hepatitis, and lymphadenopathy.
The patient’s ANA and blood cultures were negative.
Her RegiSCAR-Group Diagnosis Score was 5, suggesting
probable DRESS (Table 1). LTA testing showed a
substantial decline in viability of the patient’s white blood
cells compared to controls when exposed to penicillin
and its metabolites (Fig. 2). The patient received systemic
corticosteroids, resulting in normalization of lab work
and improvement of symptoms. Lifelong penicillin
avoidance was advised along with the notation in medical
records of penicillin allergy. Maternal samples also

Fig. 1 Case 1 lymphocyte toxicity assay
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showed concentration-dependent decreased cell viability.
The patient’s mother had no prior adverse reactions to
antibiotics.
Case 1 lymphocyte toxicity assay results show a
concentration-dependent decline in patient and parent
lymphocyte viability when incubated with penicillin and
activated mammalian-derived microsomes. Compared to
control cells, the patient and parent cells demonstrated
decreased viability when incubated with penicillin, and
showed further decline when incubated with penicillin
metabolites generated by the activated microsomes.
Case 2 lymphocyte toxicity assay results show a
concentration-dependent decline in patient and parent
lymphocyte viability when incubated with penicillin and
activated microsomes. Compared to control cells, the
patient and parent cells demonstrated decreased viability
when incubated with penicillin, and showed further
decline when incubated with penicillin metabolites
generated by the activated microsomes.

Discussion
Few cases of DRESS associated with amoxicillinclavulanate have been published, particularly in children.
One case report described a 12-year-old male who
received empiric amoxicillin-clavulanate for a fever
and cough and subsequently developed DRESS within
a ten day period [7]. Similarly, our patients developed
symptoms within two weeks as opposed to the typically
reported 2 to 6 week period, supporting the possibility of
a shorter latency period for DRESS induced by antibiotics
in children [2, 4].
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Fig. 2 Case 2 lymphocyte toxicity assay

Research on the sensitivity and specificity of the LTA
is limited, partly due to the test being limited to wellequipped research centers and validated only for few
classes of drugs. In their retrospective study, Elzagallaii
et al. found that amongst 13 patients with re-exposure
events to beta-lactam antibiotics, the LTA showed a
sensitivity of 40% and a specificity of 100% [8]. The cases
we have described further suggest that the LTA may be a
useful tool in the evaluation of DRESS reactions.
The use of LTA to risk stratify relatives of patients
who have had DRESS has not been previously reported.
With regards to Case 1, both parents had abnormal LTA
results, suggesting a genetic contribution to the patient’s
sensitivity. An association between human leukocyte
antigen haplotypes and susceptibility to DRESS is well
established for allopurinol, carbamazepine, abacavir
and other medications, [2] although no such strong
association has yet been discovered with penicillinclass antibiotics. The LTA test supports the hapten
hypothesis, i.e. that reactive metabolites contribute to
the development of DRESS via hapten formation and
assessment of white blood cell toxicity can serve to
identify phenotypic vulnerability in patient cells [8].

shorter latent period in DRESS induced by antibiotics.
We have also shown that the LTA can be a helpful tool
to confirm DRESS reactions, and that testing may have
potential implications for family members.

Conclusions
Amoxicillin-clavulanate is a commonly used antibiotic
and the cases we have described suggest that it should
be recognized as a potential cause of DRESS in
pediatric patients. Furthermore, these cases contribute
current literature supporting that there may be a
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